TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06085417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine + dexamethasone
Description: Vital signs were recorded before the block. Peripheral vascular access was established with a 20-gauge catheter and 0.9% NaCl crystalloid solution infusion was started. For sedation, all patients were routinely administered 1mg midazolam intravenously before the procedure. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded.~During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy.
Study: NCT05007106

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab/Vibostolimab Co-Formulation
Description: Pembrolizumab 200 mg plus vibostolimab 200 mg administered via IV infusion Q3W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg administered via IV infusion Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 20 mg, 12 mg, or 8 mg (dependent on cancer type and body weight) administered via oral capsule QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU 800 mg/m\^2/day administered via continuous IV infusion on each of days 1 to 5 Q3W for up to 35 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin administered via IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel administered via IV infusion at investigator's choice of dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel administered via IV infusion at investigator's choice of dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered via IV infusion on Day 1 and Day 8 of each 3-week cycle, until PD or unacceptable toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered via IV infusion at investigator's choice of dose and frequency

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: For participants who cannot receive paclitaxel due to hypersensitivity or adverse event (AE), docetaxel administered via IV infusion Q3W, Day 1 of each cycle for up to 5 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (or biosimilars such as MVASI®, Zirabev®, Aybintio®, ALYMSYS®, Abevmy®, Onbevezy®, Vegzelma®) administered via IV infusion Q3W; Day 1 of each 3-week cycle for up to 15 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine administered via oral tablet twice daily on Days 1 to 14 of each cycle (Q3W) for up to 35 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin administered via IV infusion Q3W up to 35 cycles
Study: NCT05167227

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extension for Community Healthcare Outcomes
Description: ECHO is a technology enabled multi-disciplinary team-based care model centered on case-consultation and peer-to-peer sharing of emerging best practices (i.e., teleECHO) to support management of complex cases associated with Long COVID, ME/CFS, and other PIFI.
Study: NCT05134740

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAA-specific CTLs
Description: Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dose level:~2 x 10\^7/m2
Study: NCT06650306

Intervention type: OTHER
Intervention: This study does not involve any interventions
Description: This study does not involve any interventions

Intervention type: OTHER
Intervention: This study does not involve any interventions
Description: This study does not involve any interventions

Intervention type: OTHER
Intervention: This study does not involve any interventions
Description: This study does not involve any interventions
Study: NCT06085417

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine + magnesium sulphate
Description: Vital signs were recorded before the block. Peripheral vascular access was established with a 20-gauge catheter and 0.9% NaCl crystalloid solution infusion was started. For sedation, all patients were routinely administered 1mg midazolam intravenously before the procedure. Patients' ASA score, demographic data (age, height, weight), systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), heart rate (HR), SpO₂, sensory and motor block onset times , need for additional sedation, side effects and complications, if any, were recorded. The patients' postoperative sensory block and motor block resolution times, VAS scores at the 0th, 3rd, 6th, 12th and 24th postoperative hours, total opioid and NSAID requirements in the first 24 hours, and analgesia durations were recorded.~During the perioperative period, all patients were monitored for side effects such as nausea, vomiting, tinnitus, metallic taste in the mouth, and drug allergy.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: bupivacaine
Description: bupivacaine
Study: NCT06651398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lenient diet
Description: The interventional goup receives the lenient diet instructions and will eat a light meal until 18h on the day before the colonoscopy. The first dose of Plenvu will be started at 20h. All the other bowel preparation instructions will be the same as in the control group.
Study: NCT06264362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored Physical Activity Program
Description: Adaptation of physical activity as an intervention for pain management using the 3-Step Tailored Approach: assessing in Step 1 the Person Living with Dementia (PLWD), in Step 2 the Environment, and in Step 3 the Caregiver. With this approach, traditional exercises can be adapted to 1) functional activities (e.g., stair climbing) that are tailored to the interests (e.g., dancing, boxing) and preserved abilities of PLWD; 2) preferred and well-tolerated environments (e.g., home); and 3) account for extent and type of interventionist and caregiver involvement.
Study: NCT04719728

Intervention type: DIAGNOSTIC_TEST
Intervention: Aided pure tone audiometry
Description: aided response, speech, evoked potential

Intervention type: DIAGNOSTIC_TEST
Intervention: Aided pure tone audiometry
Description: aided response, speech, evoked potential
Study: NCT06358157

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ladera LBC System
Description: Use of the Ladera LBC System to close the femoral arteriotomy
Study: NCT05887752

Intervention type: OTHER
Group type: OTHER
Intervention: Standard rehabilitation
Description: Carried out 3h/day, 5 days/week at the Montecatone Institute. It implies a multiprofessional approach through:~* physiotherapy;~* occupational therapy;~* sports rehabilitation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard rehabilitation
Description: Carried out 3h/day, 5 days/week at the Montecatone Institute. It implies a multiprofessional approach through:~* physiotherapy;~* occupational therapy;~* sports rehabilitation.

Intervention type: DEVICE
Group type: OTHER
Intervention: Hunova® rehabilitation
Description: Performed in a dedicated gym of the Montecatone Institute, 1 hour/day, 5 days/week, in the presence of a physiotherapist. Depending on the improvement of the person and of his skills acquisition, the degree of tilting of the Hunova® seat in the various planes may vary.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hunova® rehabilitation
Description: Performed in a dedicated gym of the Montecatone Institute, 1 hour/day, 5 days/week, in the presence of a physiotherapist. Depending on the improvement of the person and of his skills acquisition, the degree of tilting of the Hunova® seat in the various planes may vary.
Study: NCT06551948

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: psyllium
Description: 15 g psyllium

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: methylcellulose
Description: 15 gm methylcellulose

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: 15 g maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: inulin
Description: 15g inulin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: inulin
Description: 15g inulin
Study: NCT04736147

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JNJ-64300535
Description: JNJ-64300535 injection will be administered intramuscularly.
Study: NCT05183139

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets
Study: NCT06012188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sleep toy
Description: The parents of the children in the experimental group will be given a sleeping companion toy to present to their children. At the end of 15 days, the Children's Sleep Habits scale will be applied as a post-test to evaluate the effect of the sleep companion toy.
Study: NCT06551948

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: inulin
Description: 15g inulin
Study: NCT05965401

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic-guided dosing
Description: SSRI dosing based on Clinical Pharmacogenetics Implementation Consortium's SSRI dosing guidelines.
Study: NCT06292039

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human-Centered Injury Thrivorship Pathway
Description: Enrollment in the human-centered injury thrivorship pathway.
Study: NCT05965401

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: GLAD-PC guided dosing
Description: SSRI dosing based on GLAD-PC clinical practice guidelines
Study: NCT05454488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Focal Cryoablation
Description: Participants will have the Focal cryoablation placed by the needles in such a way that the area of affected tissue is much smaller and focus just on the tumor tissue and surrounding area

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Participants will receive a prostate biopsy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-life Questionnaires
Description: Participants will fill out questionnaires.
Study: NCT06651723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrush type
Description: The participants will use either an electric soft brush (test) and soft manual brush (control).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrush type
Description: The participants will use either an electric soft brush (test) and soft manual brush (control).
Study: NCT06653660

Intervention type: OTHER
Intervention: Clinical examination
Description: For the aim of the present study, we will follow-up children born alive in the TIMOUN cohort at peripubertal age. Questionnaires will be administered to parents on the child's health and lifestyle. Stature-weight anthropometric and cardio-dynamic measurements of the child will be obtained. Scores on three cognitive tests will be obtained. Furthermore, steroid hormones and chlordecone in the child's peripheral blood will be determined.
Study: NCT06652997

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPH3348
Description: Single oral administration of SPH3348 tablets（480mg） under fasting and fed conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPH3348
Description: Single oral administration of SPH3348 tablets（480mg） under fasting and fed conditions
Study: NCT06569160

Intervention type: DEVICE
Group type: OTHER
Intervention: UVGI (Ultra-Violet Germicidal Irradiation Device)
Description: Retirement homes are equipped with numerous airborne pathogen inactivation devices using UVGI.

Intervention type: DEVICE
Group type: OTHER
Intervention: UVGI (Ultra-Violet Germicidal Irradiation Device)
Description: Retirement homes are equipped with numerous airborne pathogen inactivation devices using UVGI.
Study: NCT06568497

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Food

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Food

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food
Description: Food
Study: NCT05187507

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the effectiveness of low- fluoridated toothpaste.
Description: Children will be given low- fluoridated toothpaste, plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness).

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of the effectiveness of fluoridated toothpaste.
Description: Children will be given e fluoridated toothpaste, plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness).
Study: NCT05327400

Intervention type: OTHER
Intervention: Pathological
Description: The pancreatic cancer cohort and the healthy cancer-free patient cohort were divided according to pathology reports
Study: NCT04816357

Intervention type: OTHER
Intervention: Questionaire
Description: only questionaire

Intervention type: OTHER
Intervention: Questionaire
Description: only questionaire
Study: NCT04705545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transpalatal arch group
Description: transpalatal arch is a 1.0 mm stainless steel wire connecting the upper permanent first molar, with a U loop pointing posteriorly, soldered to the palatal side of the molar bands.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nance button
Description: Nance button is a 1.0mm stainless steel wire connecting the upper permanent first molar, with a Nance button incorporated in the middle of the wire, soldered to the palatal side of the molar bands
Study: NCT05050188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H008
Description: Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H008
Description: Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H008 placebo
Description: Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H008 placebo
Description: Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: Drug administration after a minimum 10-hour overnight fasting. Subjects will be instructed to take the drugs with approximately 240 ml (8 oz) room temperature water
Study: NCT06074016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolmitriptan intranasal.
Description: Zolmitriptan nasal spray is supplied in a single-use, ready-to-use spray unit. It is administered in one nostril. The full protocol will explain how to use it. Following drug administration, study subjects will continue to fast for a minimum of 4h and snacks and standard meals may be served at scheduled times after drug administration (snack: +4h; lunch: +7h; snack: +10h). Liquid intake will not be allowed from 2h before to 2h after drug administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolmitriptan oral.
Description: Zolmitriptan 5 mg orally disintegrating tablet is to be taken without liquids. For oral administration, each tablet will be placed in the top of the tongue without any liquid and will disperse in a matter of seconds, then be swallowed with saliva. Following drug administration, study subjects will continue to fast for a minimum of 4h and snacks and standard meals may be served at scheduled times after drug administration (snack: +4h; lunch: +7h; snack: +10h). Liquid intake will not be allowed from 2h before to 2h after drug administration.
Study: NCT05706259

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soft gelatin 200000 IU vitamin D3 capsule
Description: Weekly single dose for 3-weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Orodispersible (sachet) 200000 IU vitamin D3
Description: Weekly single dose for 3-weeks
Study: NCT05187507

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the effectiveness of theobromine toothpaste (2%) toothpaste.
Description: Children will be given theobromine toothpaste(2%),plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the effectiveness of theobromine toothpaste(4%) toothpaste.
Description: Children will be given theobromine toothpaste(4%),plaque score in groups will be assess pre given toothpaste in baseline,aweek,2week,and after 3weeks by using the TMQHPI for both buccal and lingual surface.~Gingivalitis will be assess pre given toothpaste,aweek,2weeks,and after 3weeks by using gingival index (loe and silness).
Study: NCT06604299

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation-enhanced Cognitive Behavioral Therapy
Description: Self-guided online intervention
Study: NCT06653829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPARK
Description: A gamified augmented reality activity to recapitulate the beginning activation and engagement phase of each recovery-oriented cognitive therapy (CT-R) session
Study: NCT06653881

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ARCHWIRE
Description: Alignment efficiency of the archwires will be compared using little's irregularity index between the two groups

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ARCHWIRE
Description: Alignment efficiency of the archwires will be compared using little's irregularity index between the two groups
Study: NCT06652633

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: GLPG CAR T-cell therapy
Description: No investigational products will be administered to participants in this study.
Study: NCT06593366

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal Microbiota Transplant
Description: An investigational biologic comprised of 15.0g of dried healthy donor stool contained within a size 00 gelatin capsule, to be taken twice per day, twice per week over an 8-week duration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo capsules (OPC) containing methylcellulose, to be taken twice per day, twice per week over an 8-week duration.
Study: NCT06653244

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection
Description: dexmedimidine infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection
Description: dexmedimidine infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Injection
Description: dexmedimidine infusion
Study: NCT05572814

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Decision Support
Description: Prompts will be provided to clinicians signaling gaps in guideline-directed care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Referral
Description: Patients will be referred to an interdisciplinary, expert guideline-directed medical therapy team
Study: NCT06130839

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rocker board training
Description: Then intervention will be applied to the perturbation group as mention below at Rocker board (50 x 45 cm).the group will perform 36 sessions (4 times per week over 8 weeks) and effects of interventions will be measured before treatment, at 4th and after8th week (pre, mid and post intervention). Trunk control exercises on Rocker Board in standing position first in medio-lateral direction for 10 min and then in anterio-posterior direction for 10 min with breaks in between.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stable surface training
Description: the group will perform 36 sessions (4 times per week over 8 weeks) and effects of interventions will be measured before treatment, at 4th and after 8th week (pre, mid and post intervention).
Study: NCT06613412

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Remote Robotic Bronchoscopy system
Description: Utilization of a remote robotic bronchoscopy system for the biopsy of patients with pulmonary peripheral lesions
Study: NCT05413395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: topical colloidal oatmeal formulation with a modified plant oil
Description: Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation with a modified plant oil (Activated Oil, AO). The AO contains proprietary blends of plant oils that have selective antimicrobial properties.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: topical colloidal oatmeal formulation
Description: Standard-of-care (SOC), over-the-counter (OTC) topical colloidal oatmeal formulation